GlassScriptPhysician profile
Roy H Kim
NPI 1922156694
$4,591.90
in general payments reported to CMS, 2019-2025
20 companies · $1,224 in 2025
The $1,224 reported for 2025 was more than what 93% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $753 · 2020: $78.95 · 2021: $366 · 2022: $635 · 2023: $552 · 2024: $982 · 2025: $1,224.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,688 · Travel and Lodging: $70.42.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,687.94 |
| Travel and Lodging | $70.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $975.94 | 2021-2025 | Cequa |
| Alcon Vision LLC | $704.56 | 2019-2025 | Clareon Panoptix Pro, Clareon, Tryptyr |
| Sight Sciences, INC. | $467.46 | 2019-2022 | |
| Biotissue Holdings INC. | $437.00 | 2019-2025 | |
| Bausch & Lomb Americas INC. | $413.69 | 2024-2025 | Miebo, Xiidra, Vyzulta |
| Tarsus Pharmaceuticals, INC. | $235.59 | 2024-2025 | Xdemvy |
| Johnson & Johnson Vision Care, INC. | $228.93 | 2019-2022 | |
| Abbvie INC. | $213.81 | 2022-2025 | |
| Dompe US, INC. | $157.89 | 2025 | Oxervate |
| Oyster Point Pharma, INC. | $133.71 | 2022-2024 | Tyrvaya |
| Hoffmann-La Roche Limited | $125.00 | 2019 | |
| Novartis Pharmaceuticals Corporation | $104.53 | 2021-2023 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $103.79 | 2019 | |
| Coopervision INC. | $84.26 | 2020-2025 | Myday Contact Lens, Misight Contact Lens |
| Aerie Pharmaceuticals, INC. | $72.91 | 2019-2021 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Thea Pharma INC. | $46.46 | 2023-2024 | Iyuzeh |
| Allergan, INC. | $28.43 | 2020 | |
| Maculogix, INC. | $21.88 | 2020 | |
| Menicon America INC | $20.73 | 2019 | |
| Harrow Eye, LLC | $15.33 | 2025 | Vevye |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roy Kim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.